— Sanofi (NASDAQ: SNY) reported net loss of EUR 10 million or EUR 0.01 per share for the fourth quarter of 2019, on IFRS basis, down 103.9.% and 105% respectively, from fourth quarter of 2018.
— Business EPS, a non-GAAP measure, grew 17% at constant exchange rates to EUR 1.34.
— IFRS net sales, on a reported basis, increased 6.8% year-over-year to EUR 9.61 billion.
— Sanofi Genzyme sales rose 19.7% annually, aided by strong growth of 135% in Dupixent global sales.
— Vaccine sales increased 22%, reflecting majority of U.S. influenza vaccine shipments in Q4.
— CHC sales down 5.2%, mainly due to Zantac voluntary recall, non-core divestments and changing regulatory requirements.
— For FY20, Sanofi expects business EPS to grow about 5%, at constant exchange rates.
— SNY stock was up about 4% in the pre-market trading session.
Most Popular
Key highlights from Southwest Airlines (LUV) Q3 2021 earnings results
Southwest Airlines Co. (NYSE: LUV) reported third quarter 2021 earnings results today. Operating revenue increased 161% year-over-year to $4.7 billion. The company reported a net income of $446 million, or
What happened when Alaska Air reported Q3 results
Alaska Air (NYSE: ALK) reported third-quarter 2021 financial results before the regular market hours on Thursday. The aviation company reported Q3 revenue of $1.95 billion, up over 260% year-over-year and
Infographic: AT&T reports Q3 earnings
AT&T (NYSE: T) reported Third-quarter 2021 financial results before the regular market hours on Thursday. The telecommunications giant reported Q3 revenue of $39.9 billion, down by 5.7% reflecting the company's
